Stem Cell Educator Therapy
Type 1 Diabetes
Key Facts
About Throne Biotechnologies
Throne Biotechnologies is pioneering a unique 'immune reset' therapy using its patented cord blood-derived stem cells (CB-SCs). The company's lead program, Stem Cell Educator Therapy, has demonstrated safety and efficacy in over 200 patients across international clinical trials and has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for type 1 diabetes. Founded in 2021 and based in San Diego, Throne is a private company leveraging a decade of clinical data to advance multiple Phase 2 trials towards commercialization in large autoimmune disease markets.
View full company profileAbout Throne Biotechnologies
Throne Biotechnologies is pioneering a unique 'immune reset' therapy using its patented cord blood-derived stem cells (CB-SCs). The company's lead program, Stem Cell Educator Therapy, has demonstrated safety and efficacy in over 200 patients across international clinical trials and has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for type 1 diabetes. Founded in 2021 and based in San Diego, Throne is a private company leveraging a decade of clinical data to advance multiple Phase 2 trials towards commercialization in large autoimmune disease markets.
View full company profileAbout Throne Biotechnologies
Throne Biotechnologies is pioneering a unique 'immune reset' therapy using its patented cord blood-derived stem cells (CB-SCs). The company's lead program, Stem Cell Educator Therapy, has demonstrated safety and efficacy in over 200 patients across international clinical trials and has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for type 1 diabetes. Founded in 2021 and based in San Diego, Throne is a private company leveraging a decade of clinical data to advance multiple Phase 2 trials towards commercialization in large autoimmune disease markets.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| MSC‑Diabetes | Advancells | Phase 1 |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Pediatric Indications (<2 years) | Tandem Diabetes | Research |
| Icovamenib (BMF-219) | Biomea Fusion | Phase 2 |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |